Wall Street Zen cuts Enanta Pharmaceuticals stock to Sell. Consensus target is USD 19.00.

Published on 10/15/2026 at 21:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fiscal third-quarter revenue was USD 14.36 million on June 30, 2026. Enanta Pharmaceuticals stock costs EUR 10.25 on October 15, 2026.

Analyst rating and reporting date

Wall Street Zen changed its Enanta Pharmaceuticals rating on October 11, 2026.
Fiscal third-quarter revenue reached USD 14.36 million on June 30, 2026.
Enanta Pharmaceuticals stock was at EUR 10.25 at Lang & Schwarz on October 15, 2026 at 9:34 p.m. CEST.
The next earnings date is November 16, 2026.

ENTA, US29251M1062, Illustration mit AI erstellt.

Wall Street Zen downgraded Enanta Pharmaceuticals from Hold to Sell on October 11, 2026, while the consensus target remained USD 19.00, according to MarketBeat. Enanta Pharmaceuticals stock was trading at EUR 10.25 at Lang & Schwarz on October 15, 2026 at 9:34 p.m. CEST.

Revenue fell to USD 14.36 million

Enanta reported USD 14.36 million in revenue for its fiscal third quarter ended June 30, 2026, down 16.32 percent from USD 17.16 million in the fiscal second quarter ended March 31, 2026. The company recorded a net loss of USD 19.50 million, or USD 0.67 per diluted share, in the fiscal third quarter. These figures are reported by Yahoo Finance.

Nasdaq price stays near the yearly low

The Nasdaq quote was USD 11.45 at 3:39 p.m. ET on October 15, 2026. That placed the stock between its USD 10.20 52-week low and USD 17.15 52-week high, while the year-to-date performance stood at minus 29.11 percent. The euro quotation and the Nasdaq quotation are separate market references.

Cash, valuation and next date

Enanta's market capitalization was USD 333.4 million as of October 15, 2026, and its trailing price-to-earnings ratio was minus 4.75. The company had USD 33.42 million in cash at the end of the fiscal third quarter and used USD 9.97 million in operating cash flow during that quarter. Yahoo Finance lists November 16, 2026 as the estimated next earnings date.

Comparison with peers

Enanta Pharmaceuticals (USD): P/E minus 4.75, market capitalization USD 333.4 million.
Gilead Sciences (USD): plus 3.14 percent, P/E minus 59.29, market capitalization USD 196.4 billion.
Bristol-Myers Squibb (USD): plus 2.90 percent, P/E 13.43, market capitalization USD 124.6 billion.

What the price signals

Enanta's latest quarterly revenue and cash position show a company still funding clinical development while operating losses remain substantial. The rating change adds a negative analyst signal, but the USD 19.00 consensus target cited by MarketBeat remains above the Nasdaq quote of USD 11.45. That target is a consensus figure, not a guarantee of future performance.

The further course of trading is shown by the continuously updated real-time quote of Enanta Pharmaceuticals stock.